Otsuka PharmaceuticalTYO: 4578
Also known as: Otsuka Holdings Co., Ltd., McQuade Center for Strategic Research and Development
Otsuka Pharmaceutical Co., Ltd. is a Japanese multinational pharmaceutical company (parent: Otsuka Holdings, TYO: 4578) with a core focus on neuropsychiatry, oncology, and cardiovascular/renal medicine. It entered the psychedelic medicine space by acquiring Canadian biotech Mindset Pharma for ~CAD $80M (~USD $59M) in September 2023, giving it exclusive rights to MSP-1014 and a broader pipeline of novel 5-HT2A agonists. The deal was seeded by an earlier $5M joint development agreement between Mindset and the McQuade Center for Strategic Research and Development (an Otsuka R&D vehicle). MSP-1014 is a Phase 2 psilocin prodrug for MDD, with trials underway in the UK.
Drug Pipeline
1MSP-1014
PsilocybinMajor depressive disorder (MDD). Psilocin prodrug (novel chemical entity, rapidly metabolized to psilocin). Adaptive Phase IIa/IIb open-label MAD dose-finding (30/50/70 mg) + double-blind RCT component in UK (MHRA-approved June 2023). Delivered with Acceptance and Commitment Therapy (ACT). No topline results publicly released as of Q1 2026. Developed by Mindset Pharma, acquired by Otsuka Pharmaceutical Sept 2023.
Quick Facts
- Type
- Big Pharma
- Ticker
- TYO: 4578
- Lead Stage
- Phase II
- HQ
- 2-9 Kanda Tsukasa-cho, Chiyoda-ku, Tokyo 101-8535, Japan, Japan
- Website
- Visit